TITLE:
Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis

CONDITION:
Secondary Hyperparathyroidism

INTERVENTION:
paricalcitol injection

SUMMARY:

      The purpose of this study is to see if Zemplar, a vitamin D medication, safely and
      effectively decreases parathyroid hormone in children ages 2-20 with End Stage Renal
      Disease.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 2 Years to 20 Years
Criteria:

        Subjects ages 2-20 with ESRD on hemodialysis with Secondary hyperparathyroidism
      
